X4 Pharmaceuticals, Inc Q2 FY2023 earnings call

Paula Ragan discussed updates on the second quarter, including ongoing chronic neutropenia program insights, such as minimum addressable US market for Mavorixafor in CN populations, emerging data from Phase II trial, and regulatory update for Phase III trial in 2024. She also mentioned successful Phase III WHIM trial with positive data, plan to submit US NDA for Mavorixafor in WHIM syndrome, received additional patent for Mavorixafor, and appointment of new Chief Medical Officer Dr. Christophe Arbet-Engels. Adam Mostafa covered financial highlights: completed pipe financing raising ~$65 million, added to Russell 3000 Index, completed $115 million debt facility with Hercules Capital, and cash position as of June 30, 2023 was $142.3 million. Murray Stewart shared emerging Phase II trial data showing Mavorixafor increased ANC counts durably, enabled reduction in G-CSF dosing, favorable safety profile, and details on Phase III trial design.

No detailed product segment financial performance provided in the transcript.

Planning to submit US NDA for Mavorixafor in WHIM syndrome. Intend to initiate Phase III trial in chronic neutropenia in the first half of 2024. Plan to provide update on launch readiness, physician outreach, and WHIM market in third quarter earnings call.

Forward-looking statements subject to risks and uncertainties as detailed in X4's filings with the SEC, including potential differences between forecasted and actual results; uncertainties in regulatory approval process and clinical trial outcomes.

Q: Stephen Willey asked about GCSF tapering threshold and confidence in ANC levels.

A: Murray Stewart responded on tapering and confidence.

Q: Kristen Kluska asked about Phase 3 protocol design, infection data, and definition of severe infections.

A: Murray Stewart and Mark Baldry answered.

Q: Ted Tenthoff asked about NDA status and outcome.

A: Murray Stewart responded.

Q: Mark Brown asked about enrollment process and GCSF sparing ability.

A: Murray Stewart answered.

Q: Mayank Mamtani asked about NDA package including infection data and market research perspective.

A: Paula Ragan and Murray Stewart answered.

Q: Trevor Allred asked about FDA feedback on Phase 3 trial design.

A: Mark Baldry answered.

Q: Mayank Mamtani (via Madison) asked about NDA package and label expansion.

A: Paula Ragan answered.

Q: RK asked about additional indications for label expansion.

A: Paula Ragan answered.